CTLA4 and COVID-19: Despite these limits, they have generally shown that the COVID-19 vaccine is immunogenic in most patients with ARD, and different factors associated with a blunted vaccine response have been identified, such as anti-CD20 or CTLA4-Ig therapy [11,12,13].